This Viewpoint discusses the unfairness of current CAR T-cell therapy allocation practices and offers alternative methods to more fairly allocate therapy.
Transplant recipients, cancer patients and millions of other Americans with risk factors feel ignored and abandoned as their neighbors, and their government, seek a return to normal.